On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details

NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin”

NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial”

Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial

Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed A recent study by the Washington University School of Medicine found that the length of survivability appeared to improve when the standard chemotherapy regimen was given … Continue reading “Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021

GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021 The company is continuing its pre-clinical work on WP1244 during 2021 and 2022 CNS Pharmaceuticals participated in two virtual … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021”

NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug candidate, Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol. The protocol will be used in the planned forthcoming … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials”

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants

Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma (“GBM”) patients Glioblastomas are a type of brain cancer that have continued to elude effective therapy over the past century … Continue reading “CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants”

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in First-Ever Emerging Growth Virtual Conference

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco will be presenting at the inaugural Emerging Growth Virtual Conference. Scheduled for March 17–18, the virtual conference is presented by M Vest LLC and Maxim Group LLC. The conference agenda includes roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A’s, and presentations … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in First-Ever Emerging Growth Virtual Conference”

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leverages ‘Absolute Powerhouse Compound’ as IND Status Paves Way for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco, in a recent podcast, showed his excitement at news that the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status. The IND designation clears the way for the company to start human clinical trials and to ship the experimental drug across state lines … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leverages ‘Absolute Powerhouse Compound’ as IND Status Paves Way for Clinical Trials”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) Get the Green Light for Clinical Trials’ Protocols from Ethics Panels

CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44% CNSP has sublicensed Berubicin to WPD Pharmaceuticals in … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) Get the Green Light for Clinical Trials’ Protocols from Ethics Panels”

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Upcoming H.C. Wainwright Global Life Sciences Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the company’s CEO, John Climaco, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. According to the update, CNSP … Continue reading “NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Upcoming H.C. Wainwright Global Life Sciences Conference”

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217